Co-grinding with Cyclodextrin as a Nanoparticle Preparation Method of a Poorly Water Soluble Drug

  • Yuichi Tozuka
  • Arpansiree Wongmekiat
  • Keiko Sakata
  • Kunikazu Moribe
  • Toshio Oguchi
  • Keiji Yamamoto
Original Article


The method of co-grinding with cyclodextrins (CDs) was applied to a poorly water soluble drug, ONO-8713 (solubility; 0.92 μg/ml in H2O at 25°C) as a method to prepare nanoparticles. ONO−8713 was coground with various CDs in a vibration mill. α−Cyclodextrin, β−CD,$-CD, CD derivatives and some sugars were used as co-grinding additives. Suitable moisture content in the co-grinding system was required to achieve maximum nanoparticle yield. When ONO-8713 was co-ground with β-CD (molar ratio of β-CD:drug=5:1) at 12% moisture, 85% of drug recovered as nanoparticles with a mean particle size of 120 nm. Nanoparticle yield achieved 90% when hydroxypropyl-β-CD was used as a co-grinding additive. It was found that the amount of drug nanoparticles depended on the characteristics of CDs. This phenomenon was probably due to the difference in the cavity size of CDs along with the variation of substitution groups that affected the interaction between CDs and drug, and the affinity between CD and drug molecules. Zeta potential analysis suggested that CD would form a layer covering on the particle surface and alter the charge of the particles, improving the stability and total yield of the nanoparticle.


co-grinding cyclodextrin moisture condition nanoparticle ONO-8713 poorly water soluble drug 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    El-Shabouri, MH 2002STP Pharma Sci1297Google Scholar
  2. 2.
    Grcic, FJ, Voinovich, D, Moneghini, M, Lacan, MB, Magarotto, L, Jalsenjak, I 2000Eur J Pharm Sci9373Google Scholar
  3. 3.
    Kayrak, D, Akman, U, Hortaçsu, O 2003J Supercrit Fluids2617Google Scholar
  4. 4.
    Charoenchaitrakool, M, Dehghani, F, Foster, N.R, Chan, HK 2000Ind Eng Chem Res394794Google Scholar
  5. 5.
    Nykamp, G, Carstensen, U, Muller, BW 2002Int J Pharm24279Google Scholar
  6. 6.
    Watanabe, T, Ohno, I, Wakiyama, N, Kusai, A, Senna, M 2002Int J Pharm241103Google Scholar
  7. 7.
    Nakai, Y, Yamamoto, K, Terada, K, Akimoto, K 1984Chem Pharm Bull32685Google Scholar
  8. 8.
    Oguchi, T, Tozuka, Y, Hanawa, T, Mizutani, M., Sasaki, N, Limmatvapirat, S, Yamamoto, K 2002Chem Pharm Bull50887Google Scholar
  9. 9.
    Limmatvapirat, S, Yonemochi, E, Oguchi, T, Yamamoto, K 1997Chem Pharm Bull451358Google Scholar
  10. 10.
    Kubo, H, Osawa, T, Takashima, K, Mizobe, M 1996Chem Pharm Bull19741Google Scholar
  11. 11.
    Sugimoto, M., Okagaki, T, Narisawa, S, Koida, Y, Nakajima, K 1998Int J Pharm16011Google Scholar
  12. 12.
    Yamada, T, Saito, N, Imai, T, Otagiri, M 1999Chem Pharm Bull471311Google Scholar
  13. 13.
    Wongmekiat, A., Tozuka, Y, Oguchi, T, Yamamoto, K 2002Pharm Res191867Google Scholar
  14. 14.
    Wongmekiat, A, Tozuka, Y, Oguchi, T, Yamamoto, K 2003Int J Pharm26585Google Scholar
  15. 15.
    Itoh, K, Pongpeerapat, A, Tozuka, Y, Oguchi, T, Yamamoto, K 2003Chem Pharm Bull51171Google Scholar
  16. 16.
    McCandless, R, Yalkowsky, SH 1998J Pharm Sci871639Google Scholar
  17. 17.
    Dollo, G, Corre, PL, Chollet, M, Chevanne, F, Bertault, M, Burgot, JL, Verge, RL 1999J Pharm Sci88889Google Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  • Yuichi Tozuka
    • 1
  • Arpansiree Wongmekiat
    • 1
  • Keiko Sakata
    • 1
  • Kunikazu Moribe
    • 1
  • Toshio Oguchi
    • 2
  • Keiji Yamamoto
    • 1
  1. 1.Graduate School of Pharmaceutical SciencesChiba UniversityInage-kuJapan
  2. 2.Department of Pharmacy, University Hospital, Faculty of MedicineUniversity of YamanashiYamanashiJapan

Personalised recommendations